JP6211527B2 - ２−置換オレアノール酸誘導体、その調製方法及びその用途 - Google Patents

２−置換オレアノール酸誘導体、その調製方法及びその用途 Download PDF

Info

Publication number
JP6211527B2
JP6211527B2 JP2014543761A JP2014543761A JP6211527B2 JP 6211527 B2 JP6211527 B2 JP 6211527B2 JP 2014543761 A JP2014543761 A JP 2014543761A JP 2014543761 A JP2014543761 A JP 2014543761A JP 6211527 B2 JP6211527 B2 JP 6211527B2
Authority
JP
Japan
Prior art keywords
alkyl
oleanolic acid
substituted
pharmaceutically acceptable
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014543761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534268A5 (enExample
JP2014534268A (ja
Inventor
ロンツェン シュー
ロンツェン シュー
フランク ロン
フランク ロン
ホンシ ライ
ホンシ ライ
フーウェン シェ
フーウェン シェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Bensheng Pharmaceutical Co Ltd
Original Assignee
Hangzhou Bensheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Bensheng Pharmaceutical Co Ltd filed Critical Hangzhou Bensheng Pharmaceutical Co Ltd
Publication of JP2014534268A publication Critical patent/JP2014534268A/ja
Publication of JP2014534268A5 publication Critical patent/JP2014534268A5/ja
Application granted granted Critical
Publication of JP6211527B2 publication Critical patent/JP6211527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014543761A 2011-12-01 2012-11-30 ２−置換オレアノール酸誘導体、その調製方法及びその用途 Expired - Fee Related JP6211527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011083288 2011-12-01
CNPCT/CN2011/083288 2011-12-01
PCT/CN2012/085652 WO2013079018A1 (zh) 2011-12-01 2012-11-30 2-位取代的齐墩果酸衍生物、及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2014534268A JP2014534268A (ja) 2014-12-18
JP2014534268A5 JP2014534268A5 (enExample) 2016-01-14
JP6211527B2 true JP6211527B2 (ja) 2017-10-11

Family

ID=48534679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543761A Expired - Fee Related JP6211527B2 (ja) 2011-12-01 2012-11-30 ２−置換オレアノール酸誘導体、その調製方法及びその用途

Country Status (7)

Country Link
US (1) US9156801B2 (enExample)
EP (1) EP2786757B1 (enExample)
JP (1) JP6211527B2 (enExample)
CN (1) CN103945852B (enExample)
DK (1) DK2786757T3 (enExample)
NO (1) NO2786757T3 (enExample)
WO (1) WO2013079018A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213531A (zh) * 2015-10-14 2016-01-06 三峡大学 木瓜总三萜及其组分在制药中的应用
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
US9969768B1 (en) * 2017-11-16 2018-05-15 King Saud University Oleanolic acid methyl ester derivatives
US10137138B1 (en) 2018-05-29 2018-11-27 King Saud University Sulfonylurea derivatives of oleanolic acid
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07583B2 (ja) * 1990-11-21 1995-01-11 北海道糖業株式会社 水溶性五環性トリテルペン包接化合物及びその製造方法並びにそれを利用した食品、飲料、口腔用組成物
CN1164609C (zh) 2002-10-24 2004-09-01 青岛海洋大学 一种齐墩果酸乳糖缀合物及其制备方法和用途
US20050143464A1 (en) * 2003-09-22 2005-06-30 Use-Techno Corporation Insulin secretion potentiator
EP2279197B1 (en) * 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN101974059A (zh) * 2010-09-10 2011-02-16 武汉巨惠绿色产业发展有限公司 一种齐墩果酸结构类似物的制备及其半合成齐墩果酸的方法
CN102133219A (zh) 2010-09-27 2011-07-27 林秀坤 齐墩果酸的抗宫颈癌作用及其药物制剂
CN102151275A (zh) 2010-11-07 2011-08-17 林秀坤 齐墩果酸的抗胰腺癌作用及其药物制剂
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途

Also Published As

Publication number Publication date
EP2786757B1 (en) 2017-08-16
EP2786757A4 (en) 2015-08-12
NO2786757T3 (enExample) 2018-01-13
JP2014534268A (ja) 2014-12-18
WO2013079018A1 (zh) 2013-06-06
US9156801B2 (en) 2015-10-13
US20140343064A1 (en) 2014-11-20
CN103945852B (zh) 2016-10-19
CN103945852A (zh) 2014-07-23
DK2786757T3 (da) 2017-11-20
EP2786757A1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
JP6043361B2 (ja) オレアノール酸アミド化誘導体、その調製方法及び使用
JP2014534268A (ja) ２−置換オレアノール酸誘導体、その調製方法及びその用途
JP6286365B2 (ja) １−オキソ／アシル化−１４−アシル化オリドニン誘導体、その調製方法及び適用
JP5976810B2 (ja) ５−置換テトランドリン誘導体、その調製方法及びその使用
JP2015504075A (ja) ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用
JP6149043B2 (ja) ２−アミノ化メチレン又は２−エステル化メチレンタンシノン誘導体、並びにその調製方法及び使用
CN102731454B (zh) 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途
US9353146B2 (en) Acylation derivatives of paridis saponins I, preparation method therefor and application thereof
WO2011143864A1 (zh) 抗癌用化合物及制备方法
JP6068472B2 (ja) アミノ化ホモハリントニン誘導体、その調製方法及び使用
JP7481263B2 (ja) チオフェン誘導体の結晶形
CN103724321B (zh) 一氧化氮和硫化氢供体型苯酞衍生物及其制备方法和用途
JP5993455B2 (ja) ホモハリントニンアシル化誘導体、その調製方法及び使用
CN107163047A (zh) 槐定胺类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170913

R150 Certificate of patent or registration of utility model

Ref document number: 6211527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees